
PRODUCT CLASSIFICATION
產(chǎn)品分類產(chǎn)品展示/ Product display
您的位置:首頁 / 產(chǎn)品展示 / / CAR T-Cell Therapy Cell Lines / 79854Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transm...

產(chǎn)品型號(hào):79854
廠商性質(zhì):生產(chǎn)廠家
更新時(shí)間:2023-11-11
訪 問 量:269
立即咨詢
聯(lián)系電話:
Anti-CD19 CAR Negative Control/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 Transmembrane Motif) is a stable cell line expressing an anti-CD19 CAR negative control and an NFAT-dependent luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without the intracellular signaling domains. The reporter cell line has been validated for anti-CD19 expression by flow cytometry, and in co-culture with target cells, such as CD19/CHO recombinant cell line the luciferase reporter gene was not activated. Anti-CD19 CAR Negative Control Jurkat/NFAT (Luciferase) Reporter Cell Line was generated by the transduction of NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) with anti-CD19 CAR negative control lentivirus.
The cell line can be used as negative control for the Anti-CD19 CAR/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1-BB-CD3ζ) (BPS Bioscience #79853).

Figure 1: Lenti-vector used to generate anti-CD19 CAR negative control lentivirus.

Figure 2. Schematic of anti-CD19 CAR negative control.
The anti-CD19 (scFv) is linked to the CD28 transmembrane motif.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
郵箱:infocn@bpsbioscience.com
傳真:
地址:上海靜安區(qū)